MAA
SUPN icon

Managed Account Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Managed Account Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$4.55M Buy
267,965
+265,830
+12,451% +$3.78M ﹤0.01% 1465
2015
Q1 		$26K Buy
2,135
+66
+3% +$624 ﹤0.01% 2700
2014
Q4 		$17K Sell
2,069
-279
-12% -$2.34K ﹤0.01% 2575
2014
Q3 		$20K Sell
2,348
-285
-11% -$2.57K ﹤0.01% 2535
2014
Q2 		$29K Sell
2,633
-179
-6% -$1.59K ﹤0.01% 2463
2014
Q1 		$25K Buy
2,812
+49
+2% +$451 ﹤0.01% 2449
2013
Q4 		$21K Buy
+2,763
New +$19.3K ﹤0.01% 2444

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Managed Account Advisors's SUPN Position: Q2 2015 in Review

Managed Account Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 12,451% in Q2 2015, buying an estimated $3.78M and bringing the position to 267,965 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Managed Account Advisors first reported a position in SUPN in Q4 2013 and has held it in 7 quarters since. 165 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

  • Managed Account Advisors held 267,965 shares of Supernus Pharmaceuticals worth $4.55M as of Q2 2015.
  • Managed Account Advisors bought 265,830 Supernus Pharmaceuticals shares in Q2 2015, an estimated $3.78M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1465 holding.
  • Managed Account Advisors first reported a position in Supernus Pharmaceuticals in Q4 2013 and has held it in 7 quarters since.
  • 165 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.